Gareth Morgan, MD, FRCP, FRCPath, PhD from the UAMS Myeloma Institute, Little Rock, AR discusses the use of FISH in multiple myeloma (MM). According to Dr Morgan, it is important to consider that there are many subtypes of MM and a precision or personalized medicine approach is therefore important. The problem about FISH is that it is slow, expensive and prone to error. When compared to molecular diagnostics and next-generation sequencing (NGS), FISH therefore becomes obsolete according to Dr Morgan. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.